Rare cancers

Federal Budget commitment to medical research funding welcome, but urgent need for gynaecological cancer investment remains

Federal Budget commitment to medical research funding welcome, but urgent need for gynaecological cancer investment remains MEDIA RELEASE 13 May 2026 Federal Budget commitment to medical research funding welcome, but urgent need for gynaecological cancer investment remains  The Australia New Zealand Gynaecological Oncology Group [...]

Federal Budget commitment to medical research funding welcome, but urgent need for gynaecological cancer investment remains2026-05-19T18:34:40+10:00

STRIVE clinical trial now available in Aotearoa New Zealand to improve outcomes in vulvar cancer

STRIVE clinical trial now available in Aotearoa New Zealand to improve outcomes in vulvar cancer Media Release - 24 February 2026 The Australian New Zealand Gynaecological Oncology Group (ANZGOG) in partnership with the Canadian Cancer Trials Group (CCTG) [...]

STRIVE clinical trial now available in Aotearoa New Zealand to improve outcomes in vulvar cancer2026-04-07T12:58:29+10:00

Recognising Diverse Needs during NAIDOC Week: Tracy’s Journey with Gynaecological Cancer

During National Aboriginal and Islanders Day Observance Committee (NAIDOC) Week, we celebrate Tracy's journey. Tracy, a proud Aboriginal woman, embodies determination and leadership. She has always been a go-getter. Unlike many in her community, she is [...]

Recognising Diverse Needs during NAIDOC Week: Tracy’s Journey with Gynaecological Cancer2024-07-09T15:54:47+10:00

New global therapy now approved for Australian patients with Leiomyosarcoma

An additional chemotherapy option for people with advanced leiomyosarcoma is now available on the Pharmaceutical Benefits Scheme (PBS). Trabectedin, (brand name - Yondelis) offers renewed hope for patients facing this rare and challenging sarcoma cancer. [...]

New global therapy now approved for Australian patients with Leiomyosarcoma2023-10-18T11:44:07+11:00

PARAGON – the study that drove ANZGOG’s position at the forefront of innovative trial designs

Led by ANZGOG co-founder Professor Michael Friedlander AM, PARAGON was one of ANZGOG's first practice-changing studies. The publications arising from the insights and data collected because of this pivotal trial continue to contribute to research on [...]

PARAGON – the study that drove ANZGOG’s position at the forefront of innovative trial designs2023-10-18T11:45:30+11:00

PEACE trial opens to recruitment

ANZGOG’s new study for patients with advanced gynaecological cancer, PEACE, has officially opened to recruitment after activating its first site, Canberra Hospital. Led by Principal Investigator Dr Alison Davis in Australia, the international study [...]

PEACE trial opens to recruitment2023-10-18T12:01:14+11:00

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment

EMBRACE is a Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2. Dr Katrin Sjoquist, Medical Oncologist [...]

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment2022-07-01T11:34:46+10:00
Go to Top